DCF Advisers LLC Has $2.41 Million Stock Position in Prothena Corporation plc (NASDAQ:PRTA)

Key Points

• DCF Advisers LLC increased its stake in Prothena Corporation by 88.4%, owning 195,000 shares following the purchase of an additional 91,500 shares in the first quarter.
• Prothena reported a net loss of ($1.12) earnings per share for the last quarter, missing the consensus estimate and showing a 5500% increase in revenue year-over-year.
• Recent analyst ratings have been mixed, with target prices for Prothena being cut significantly, including a downgrade from $30.00 to $14.00 by HC Wainwright.

DCF Advisers LLC raised its stake in shares of Prothena Corporation plc (NASDAQ:PRTA - Free Report) by 88.4% in the first quarter, according to its most recent 13F filing with the SEC. The fund owned 195,000 shares of the biotechnology company's stock after buying an additional 91,500 shares during the period. Prothena comprises about 1.2% of DCF Advisers LLC's portfolio, making the stock its 29th largest holding. DCF Advisers LLC owned 0.36% of Prothena worth $2,413,000 as of its most recent filing with the SEC.

Several other large investors also recently bought and sold shares of the business. Deutsche Bank AG raised its position in shares of Prothena by 195.7% during the 4th quarter. Deutsche Bank AG now owns 95,970 shares of the biotechnology company's stock worth $1,329,000 after buying an additional 63,512 shares in the last quarter. Barclays PLC lifted its holdings in Prothena by 10.6% during the 4th quarter. Barclays PLC now owns 105,338 shares of the biotechnology company's stock worth $1,458,000 after purchasing an additional 10,116 shares during the last quarter. Cambridge Investment Research Advisors Inc. acquired a new position in shares of Prothena in the 1st quarter worth approximately $126,000. Susquehanna Fundamental Investments LLC bought a new stake in shares of Prothena during the 4th quarter worth $1,117,000. Finally, SG Americas Securities LLC boosted its position in shares of Prothena by 92.9% in the first quarter. SG Americas Securities LLC now owns 72,559 shares of the biotechnology company's stock valued at $898,000 after acquiring an additional 34,947 shares during the period. Hedge funds and other institutional investors own 97.08% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. Jefferies Financial Group cut Prothena from a "buy" rating to a "hold" rating and set a $6.00 price target on the stock. in a report on Tuesday, May 27th. Royal Bank Of Canada reduced their price objective on Prothena from $18.00 to $10.00 and set a "sector perform" rating on the stock in a research note on Tuesday. Piper Sandler cut their target price on shares of Prothena from $110.00 to $81.00 and set an "overweight" rating for the company in a research report on Tuesday, May 27th. Oppenheimer lowered shares of Prothena from an "outperform" rating to a "market perform" rating in a report on Tuesday, May 27th. Finally, Chardan Capital reaffirmed a "buy" rating and set a $18.00 price objective on shares of Prothena in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, Prothena has a consensus rating of "Hold" and an average price target of $30.25.

Prothena Trading Down 4.3%

Shares of PRTA traded down $0.34 during midday trading on Thursday, hitting $7.58. The stock had a trading volume of 199,416 shares, compared to its average volume of 1,058,959. The business has a 50-day simple moving average of $6.07 and a two-hundred day simple moving average of $9.76. Prothena Corporation plc has a fifty-two week low of $4.32 and a fifty-two week high of $23.66. The firm has a market cap of $408.03 million, a P/E ratio of -1.34 and a beta of -0.03.

Prothena (NASDAQ:PRTA - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The biotechnology company reported ($1.86) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.11) by ($0.75). Prothena had a negative net margin of 2,929.30% and a negative return on equity of 62.17%. The company had revenue of $4.42 million for the quarter, compared to analysts' expectations of $5.36 million. On average, analysts expect that Prothena Corporation plc will post -4.04 earnings per share for the current fiscal year.

Prothena Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.